Comparison of the safety and immunogenicity of two inactivated hepatitis A vaccines

Advances in Therapy

Volumn 14, Issue 3, 1997, Pages 116-124

  Zuckerman, Jane ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Hepatitis A vaccine; Immunogenicity; Vaccine trial

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION; VIRUS HEPATITIS;

EID: 0030873293     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Zaaijer HL, Lecntvaarkuijpers A, Rotman H, Lelie PN. Hepatitis A antibody titres after infection and immunization-Implications for passive and active immunization. J Med Viral. 1993;40:22-27.
2. Delem AD. Comparison of modified HAVAB and ELISA for determination of vaccine-induced anti-HAV response. Biologicals. 1992;20:289-291.
3. Berger R, Just M, Althaus B. Time course of hepatitis A antibody production after active, passive and active/passive immunisation: the results are highly dependent on the antibody test system used. J Virol Methods. 1993;43:287-297.
4. Claesson BA, Iwarson SA. Dose response study of an inactivated hepatitis A virus vaccine. JHepatol. 1993;18:S41-S45.
5. Wiedermann G, Ambrosch F, Kollaritsch H, et al. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine. 1990;8:581-584.
6. Goubau P, Vangerven V, Safary A, et al. Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. Vaccine. 1992;10:S114-S118.
7. Scheifele DW, Bjornson GJ. Evaluation of inactivated hepatitis A vaccine in Canadians 40 years of age or more. Can Med Assoc J. 1993;148:551-555.
8. Horng YC, Chang MH, Lee CY, Safary A, André FE, Chen DS. Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers. J Gastroenterol Hepatol. 1993;8:338-341.
9. Westblom TU, Gudipati S, Derousse C, Midkiff BR, Belshe RB. Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule. J Infect Dis. 1994;169: 996-1001.
10. Ellerbeck EF, Lewis JA, Nalin DR, et al. Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A. Vaccine. 1992;10:668-672.
11. Shouval D, Ashur Y, Adler R, et al. Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. J Hepatol. 1993;18:S32-S37.
12. Jilg W, Bittner R, Schatzl H, Rasshofer R, Schmidt M, Deinhardt F. The immune response to different doses of inactivated hepatitis A vaccine J Hepatol. 1993;18:S38-S40.
13. Miller WJ, Clark W, Humi WM, Kuter B, Schofield T, Nalin DR. Sensitive assays for hepatitis A antibodies. J Med Virol. 1993;41:201-204.
14. Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis A vaccine. Lancet. 1994; 343:322-324.
15. Just M, Berger H, Drechsler H, Brantschen S, Glück R. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine. 1992; 10:737-739.
16. Glück R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest. 1992;90:2491-2495.
17. Poovorawan Y, Tieamboonlers A, Chumdermpadetsuk S, GlÜck R, Cryz SJ. Control of a hepatitis A outbreak by active immunization of high-risk susceptible subjects. J Infect Dis. 1994;169:228-229.
18. Holzer BR, Hatz C, Schmidt-Sssolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine. 1996;14:982-986.
19. Goilav C, Zuckerman JN, Lafrenz M, et al. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J Med Virol. 1995;46:287-292.
20. Van Damme P, Thoelen S, Gramm M, Meheus A. Safety and immunogenicity of a high-potency inactivated hepatitis A vaccine. J Travel Med. 1996;3:83-90.
21. Nalin DR, Kuter BJ, Brown L, et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatrie and adult populations: an overview. J Hepatol. 1993; 18:S51-S55.
22. Frosner GG, Overby LR, Flehmig B, et al. Serological investigation of patients and family contacts in an epidemic of hepatitis A. J Med Virol. 1977;1:163-173.
23. Flehmig B, Vallbracht A, Wurster G. Hepatitis A in cell culture. Propagation of hepatitis virus in human embryo kidney cells and human embryo fibroblast strains. Med Microbiol Immunol. 1981; 170:83-89.
24. Heinricy U, Hentscel J, Pfisterer M, Flehmig B. Hepatitis A: biophysical characterisation and electron microscopy of infectious hepatitis A virus. Zentrabl Bakteriol Hyg. 1983;A257:139-142.
25. Graff J, Kasang C, Normann A, Pfisterer M, Feinstone SM, Flehmig B. Mutational events in consecutive passages of hepatitis A virus strain GBM during cell culture adaptation. Virology. 1994;204:60-68.
26. Graff J, Normann A, Feinstone SM, Flehmig B. Nucleotide sequence of wild-type hepatitis A virus GBM in comparison to two cell culture-adapted variants. J Virol. 1994;68:548-554.
27. Vidor E, Fritzell B, Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infection. 1996;24:447-458.
28. Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine. 1992;10:S99-S101.
29. André FE, d'Hondt E, Delem AD, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine. 1992;10:S160-S168.
30. Safford S, Needleman SB, Decker RH. Radioimmunoassay for detection of antibody to hepatitis A virus: results of clinical evaluation. Am J Clin Palhol. 1980;74:25-31.
31. Gerety RJ, Smallwood LA, Finlayson JS, Tabor E. Standardization of the antibody to hepatitis A virus (anti-HAV) content of immunoglobulin. Dev Biol Stand. 1983;54:411-416.
32. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics. 1975;31:103-105.
33. Vidor E, Xueref C, Blondeau C, et al. Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine. Biologicals. 1996;24:235-242.